Patient Adherence To HAART Regimens: Challenges For Physician Assistants And Health Care Providers

Day, Marvin
January 2003
Internet Journal of Academic Physician Assistants;2003, Vol. 3 Issue 1, p42
Academic Journal
Patients often adhere incompletely and inadequately to highly active antiretroviral therapy (HAART) regimens used in the treatment of HIV infection. This permits the emergence of HIV variants that are resistant to current treatment. The physician assistant often assumes the responsibility for explaining to the patient the importance of adhering strictly to the regimen and for collaborating with the patient to overcome any problems. This report summarizes the major reasons for poor patient adherence regimen complexity, poor tolerability, and metabolic side effects and provides patient-friendly approaches that can be adopted in the context of the office visit to increase patients level of adherence to these challenging regimens.


Related Articles

  • Comparative Cost-Efficacy Analysis of Darunavir/ritonavir and Other Ritonavir-Boosted Protease Inhibitors for First-Line Treatment of HIV-1 Infection in the United States. Brogan, Anita J.; Mrus, Joseph; Hill, Andrew; Sawyer, Anthony W.; Smets, Erik // HIV Clinical Trials;May/Jun2010, Vol. 11 Issue 3, p133 

    Purpose: A comprehensive study comparing the costs and efficacies of darunavir/ritonavir 800/100 mg qd and the other ritonavir-boosted (/r) protease inhibitors (PIs) recommended for treatment-naïve individuals with HIV-1 infection would help health care decision makers identify the value of...

  • Neuropsychiatric Adverse Events With Ritonavir-Boosted Darunavir Monotherapy in HIV-Infected Individuals: A Randomised Prospective Study. Winston, Alan; Fätkenheuer, Gerd; Arribas, Jose; Hill, Andrew; van Delft, Yvon; Moecklinghoff, Christiane // HIV Clinical Trials;May/Jun2010, Vol. 11 Issue 3, p163 

    Background: Protease inhibitor monotherapy is an attractive treatment option for HIV-infected subjects. Data assessing neuropsychiatric events with the use of protease inhibitor monotherapy are sparse. Methods: Clinician- and patient-reported neuropsychiatric events were assessed over 48 weeks...

  • Haemostatic Activation in HIV Infected Patients Treated with Different Antiretroviral Regimens. Pan, Angelo; Testa, Sophie; Roldan, Eugenia Quiros; Tinelli, Carmine; Bodini, Umberto; Cadeo, Barbara; Carnevale, Giuseppe; Martinelli, Ida; Maserati, Renato; Morstabilini, Pietro; Seminari, Elena; Signorini, Liana; Carosi, Giampiero // Current HIV Research;Jan2008, Vol. 6 Issue 1, p70 

    HIV infected patients treated with highly active antiretroviral therapy (HAART) may be at increased risk of cardiovascular events, particularly if based upon the use of protease inhibitors (PI). We investigated the haemostatic markers of cardiovascular risk in 115 HIV infected subjects, divided...

  • Physical Symptoms, Beliefs About Medications, Negative Mood, and Long-Term HIV Medication Adherence. Gonzalez, Jeffrey S.; Penedo, Frank J.; Llabre, Maria M.; Durán, Ron E.; Antoni, Michael H.; Schneiderman, Neil; Horne, Rob // Annals of Behavioral Medicine;2007, Vol. 34 Issue 1, p46 

    Background: Near-perfect levels of HIV medication adherence are necessary for treatment to be successful. However, many patients continue to report nonadherence to HIV treatment. Purpose: This study examines the relationship between symptoms of HIV and medication adherence and evaluates beliefs...

  • Normalization of B Cell Counts and Subpopulations after Antiretroviral Therapy in Chronic HIV Disease. Moir, Susan; Malaspina, Angela; Ho, Jason; Wei Wang; DiPoto, Angela C.; O'Shea, Marie A.; Roby, Gregg; Mican, Joann M.; Kottilil, Shyam; Tae-Wook Chun; Proschan, Michael A.; Fauci, Anthony S. // Journal of Infectious Diseases;2/15/2008, Vol. 197 Issue 4, p572 

    Background. Untreated human immunodeficiency virus (HIV) disease leads to abnormalities in all major lymphocyte populations, including CD4+ T cells, CD8+ T cells, and B cells. However, little is known regarding the effect of antiretroviral therapy (ART)-induced decrease in HIV viremia on B cell...

  • Reduced Risk of Tuberculosis among Brazilian Patients with Advanced Human Immunodeficiency Virus Infection Treated with Highly Active Antiretroviral Therapy. Santoro-Lopes, Guilherme; De Pinho, Ana Maria Felix; Harrison, Lee H.; Schechter, Mauro // Clinical Infectious Diseases;2/15/2002, Vol. 34 Issue 4, p543 

    Presents information on a study which assessed the effect of combination antiretroviral therapy on the risk of tuberculosis among patients with HIV infection in Brazil. Use of highly active antiretroviral therapy for the treatment of HIV infection; Transmission of mycobacterium tuberculosis in...

  • Ambitious plans to roll out ARVs.  // HIV Australia;Mar-May2004, Vol. 3 Issue 3, p5 

    Reports on the plan to launch antiviral treatment programs at several pilot centres for HIV-positive people across Zimbabwe in 2004. Support of the World Health Organization for the program; Cost of a triple generic drug treatment; Reasons for choosing the pilot sites for the program.

  • Impact of Baseline Antiretroviral Resistance Status on Efficacy Outcomes Among Patients Receiving Maraviroc Plus Optimized Background Therapy in the MOTIVATE 1 and 2 Trials. Nelson, Mark; Fisher, Martin; Gonzalez-Garcia, Juan; Rockstroh, Jürgen K.; Weinstein, David; Valdez, Hernan; Mayer, Howard; van der Ryst, Elna; Goodrich, James M.; Dang, Nathalie // HIV Clinical Trials;May/Jun2010, Vol. 11 Issue 3, p145 

    Purpose: The MOTIVATE studies assessed maraviroc with optimized background therapy (OBT) in treatment-experienced patients with R5 HIV-1. This post hoc analysis compared outcomes between patients with and without HIV-1 resistance to ε3 classes of antiretrovirals at screening...

  • High Expression of Antiviral Proteins in Mucosa from Individuals Exhibiting Resistance to Human Immunodeficiency Virus. Gonzalez, Sandra Milena; Taborda, Natalia Andrea; Feria, Manuel Gerónimo; Arcia, David; Aguilar-Jiménez, Wbeimar; Zapata, Wildeman; Rugeles, María Teresa // PLoS ONE;Jun2015, Vol. 10 Issue 6, p1 

    Background: Several soluble factors have been reported to have the capacity of inhibiting HIV replication at different steps of the virus life cycle, without eliminating infected cells and through enhancement of specific cellular mechanisms. Yet, it is unclear if these antiviral factors play a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics